127120.KQ DNA Link Inc
- Market cap
- KRW 633B
- P/E
- -
- P/B
- 6.12x
- ROE
- 8.2%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 127120.KQ undervalued?
Graham numberThe Graham number of DNA Link Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DNA Link Inc fundamental analysis
6 of 22 checks passedROE 0/2
Low return on equity (8.2%), below 10%.
ROA 1/1
Return on assets (4.5%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-0.4%) is below the industry median (4.8%).
Revenue Growth 1/2
Revenue grew 4.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (8.4%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (6.1x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
DNA Link Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an …
Full company profileDNA Link Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DNA Link Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.5B | 14.5B | 14.9B | 15.6B | 15.3B | 23.0B | 17.0B | 21.9B | 15.9B | 19.3B | 17.5B |
| Gross Profit | 417M | 6.24B | 3.88B | 2.95B | 2.33B | 6.30B | 3.16B | 5.54B | 2.81B | 3.65B | 4.68B |
| Operating Income | -8.49B | 949M | -4.40B | -8.73B | -10.6B | -6.07B | -8.88B | -5.35B | -15.1B | -12.2B | -18.0B |
| EBITDA | - | - | - | - | - | - | -6.13B | -3.81B | -8.60B | -11.5B | -9.32B |
| Net Income | -9.81B | 338M | -3.75B | -13.1B | -13.1B | -5.10B | -7.78B | -5.60B | -10.8B | -16.4B | 8.44B |
| EPS | -1,470 | 30 | -329 | -1,075 | -797 | -311 | -455 | -327 | -480 | -482 | 245 |
| Balance Sheet | |||||||||||
| Total Assets | 25.9B | 25.1B | 35.1B | 25.9B | 52.5B | 41.0B | 43.5B | 38.8B | 54.4B | 123B | 188B |
| Total Liabilities | 24.0B | 1.41B | 15.5B | 16.2B | 13.8B | 8.25B | 15.6B | 12.5B | 29.4B | 54.4B | 84.2B |
| Shareholders' Equity | 1.82B | 23.7B | 19.6B | 9.66B | 38.7B | 32.8B | 27.9B | 26.3B | 25.0B | 68.6B | 104B |
| Cash & Short-term Investments | 7.65B | 6.01B | 12.8B | 6.70B | 36.9B | 5.87B | 10.8B | 6.57B | 4.75B | 40.4B | 72.2B |
| Total Debt | - | - | 2.78B | 2.59B | 2.31B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.77B | -2.49B | -1.60B | -1.30B | 849M | -6.43B | 910M | -5.03B | -6.78B | -9.39B | -24.8B |
| Capital Expenditure | 1.35B | 753M | 2.51B | 2.58B | 1.10B | 4.02B | 4.93B | 2.88B | 16.7B | 44.1B | 16.7B |
| Free Cash Flow | - | - | - | -5.16B | -411M | -10.5B | -4.18B | -7.92B | -23.5B | -53.5B | -41.6B |
| Ratios | |||||||||||
| ROE | -540.4% | 1.4% | -19.1% | -135.8% | -33.8% | -15.6% | -27.9% | -21.3% | -43.2% | -24.0% | 8.2% |
| ROA | -37.9% | 1.3% | -10.7% | -50.6% | -24.9% | -12.4% | -17.9% | -14.4% | -19.9% | -13.4% | 4.5% |
| Net Profit Margin | -85.4% | 2.3% | -25.2% | -84.2% | -85.5% | -22.2% | -45.8% | -25.5% | -67.9% | -85.1% | 48.3% |
| Debt to Equity | - | - | 0.14x | 0.27x | 0.06x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DNA Link Inc dividends
DNA Link Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 471:443 on Oct 28, 2020.
Who owns DNA Link Inc
- Insiders 27.07%
- Institutions 2.54%
- Public & others 70.39%
- Shares outstanding 34.7M
- Free float 23.7M
DNA Link Inc company profile
- Company name
- DNA Link Inc
- Ticker
- 127120.KQ
- ISIN
- KR7127120004
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 146
- Fiscal year end
- December
- Address
- 31, Magokjungang 8-ro 3-gil, Seoul, South Korea
- Phone
- 82 2 3153 1500
- Website
- jslink.co.kr
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In addition, it provides rare earth and permanent magnets. The company was formerly known as DNA Link, Inc. and changed its name to JS Link, Inc. in April 2025. JS Link, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
DNA Link Inc management
2- Jong-Beom Lee Ph.D.Executive Director, President & CEO · born 1963
- Sunghoon ChaExecutive Director